Trial Profile
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms REVEL
- Sponsors Eli Lilly and Company
- 31 Jan 2021 Results (n=55) of subgroup analysis reporting an exploratory study of safety and efficacy in the Indian patient with Non-small cell-lung cancer, presented at the 2020 World Conference on Lung Cancer.
- 01 Jan 2021 Results of post hoc analysis evaluating healthcare resource utilization associated with second-line treatment of ramucirumab plus docetaxel in advanced non-small-cell lung cancer, published in the Supportive Care in Cancer
- 18 Oct 2017 Results of subgroup analysis reporting outcomes from patients who participated in REVEL according to their time to tumor progression (TTP) on first line therapy presented at the 18th World Conference on Lung Cancer